In a prospectus supplement dated June 4, 2021, filed with the US Securities and Exchange Commission, Aytu BioPharma, Inc. (NASDAQ: AYTU), disclosed that the Company’s clinical-stage medical device asset, an ultraviolet (UV)-A light endotracheal catheter referred to as Healight™, is being studied as a potential treatment for mechanically ventilated patients suffering from severe respiratory infections,…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
